Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.36 |
| ▸ | GIPR | P48546 | 10/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MRE11 | P49959 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001117 | 0.87 | PTPN2 (0.41) | GCGRGIPRMEN1NPC1RAB9A | |
| SCHEMBL6000660 | 0.84 | PTPN1 (0.39) | GCGRGIPRMEN1NPC1RAB9A | |
| SCHEMBL6000363 | 0.81 | CNR2 (0.35) | GCGRGIPRMEN1NPC1RAB9A | |
| SCHEMBL6000371 | 0.78 | MEN1 (0.36) | GCGRGIPRAKT1MEN1NPC1 | |
| SCHEMBL6000379 | 0.78 | PTPN2 (0.40) | AKT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6000357 | 0.77 | PTPN2 (0.36) | GCGRGIPRMEN1NPC1RAB9A | |
| SCHEMBL5999015 | 0.76 | PTPN2 (0.41) | AKT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6000427 | 0.73 | PTPN2 (0.39) | GCGRGIPRAKT1MEN1NPC1 | |
| SCHEMBL5999150 | 0.73 | ALOX5 (0.41) | NPC1RAB9ASMN1; SMN2PTPN2PTPN1 | |
| SCHEMBL6001156 | 0.72 | PTPN2 (0.48) | GCGRGIPRMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | GCGR 194/4885GIPR 138/4885AKT1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.